Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)

Hepatic Steatosis Clinical Trial

Official title:

Efficacy and Safety of Probiotic Lysate (Postbiotic and Metabiotic) Supplementation in Adults MASLD Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06352697
• Other study ID #: DELI_MASLD
• Status: Completed
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: April 2024
• Source: Bogomolets National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum lipid profile, transaminases activity and chronic systemic inflammatory markers in MASLD patients. The study will include 3 periods. Screening period of up to 1 weeks to assess the eligibility to inclusion/exclusion criteria. Treatment period for 3 month where the participants will receive a twice daily oral dose of postbiotics (cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023) at the assigned dose of 100mg or placebo in capsules. During this period monthly phone contacts will be done for assessment of compliance and safety concerns. Follow-up period of up to 3 month.

Description:

The scientific literature points to the beneficial properties of probiotics in the process of regulating metabolism, yet at the same time, some scientific papers question the effectiveness and the safety of probiotics. In turn, postbiotics and metabiotics are preparations of inanimate microorganisms and / or their components, which are directly identified with the safety of their use and the health benefits of the host. Due to the chemical structure of postbiotics and metabiotics, it is found that they have many health benefits; in particular, they have a local effect on certain tissues of the intestinal epithelium, and influence on many other organs and tissues. It is postbiotics metabolites and metabiotics structural cell fragments that create the appearance of a therapeutic effect of probiotics, which, in turn, limits the risk of introducing living microorganisms into a weakened immune defence. It should also be pointed out that postbiotics and metabiotics are more stable and have a longer shelf-life. The practical use of probiotics and the study of the mechanism of their action made lately to find that a certain level of biological activity is preserved by dead probiotic cells and even their lysates, which are the natural mixes of metabiotic and postbiotic substances; a biological activity which is strongly oriented toward gut health and immune system regulation. Because probiotic lysates demonstrated biological activity without any of the potential adverse side effects associated with live bacterial cells, one of the future goal is research of the novel postbiotics and metabiotics substances, their individual structures and biological characteristics for understanding their way of communications with host cells and microbiota representatives. Considering the high biological activity and safety of postbiotics and metabiotic substances, it can be concluded that such a treatment vector will be promising in the near future. That's why our investigation will concentrate on postbiotic, a supplement containing dry fermented cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023. Recent scientific animal studies on the stated issues point to the benefits of some postbiotics in treating metabolic disorders. The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum lipid profile, transaminases activity and chronic systemic inflammatory markers in MASLD patients. The study will include 3 periods. Screening period of up to 1 weeks to assess the eligibility to inclusion/exclusion criteria. Treatment period for 3 month where the participants will receive a twice daily oral dose of postbiotics (cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023) at the assigned dose of 100mg or placebo in capsules. All capsules will be identical with similar organoleptic characteristics (e.g., taste and appearance). Follow-up period of up to 3 month. The pre-randomization period will be designed to minimize the effects of dietary changes on metabolic markers. For this purpose, 2 weeks before the study start, after inform consent signed, patients were instructed in one-on-one sessions with a dietitian to follow a therapeutic lifestyle-change diet as classified by the NCEP. In addition, participants were instructed to continue with stable anti-hyperglycemic treatment and received standardized mild physical training for 1 hour per day. Patients who underwent the study were instructed to take the trial medication as prescribed. Throughout the study, weekly phone follow-up visits were provided for assessment of compliance, adherence to the protocol, as well as the recording of adverse events. The effectiveness of therapy was compared and evaluated separately in the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• adult participants (ages 18-70)
• presence of MASLD according to "A multisociety Delphi consensus statement", 2023;
• the diagnosis of fatty liver was based on the results of abdominal ultrasonography. Of 4 known criteria (hepato-renal echo contrast, liver brightness, deep attenuation, and vascular blurring), the participants were required to have hepato-renal contrast and liver brightness to be given a diagnosis of SLD
• fatty liver index (FLI) more than 60;
• BMI 25-39.9 kg/m2;
• aspartate transaminase (AST) and alanine transaminase (ALT) =3x upper limit of normal;
• written informed consent.

Exclusion Criteria:

• recent hepatitis, or positive screening test for hepatitis B (hepatitis B virus surface antigen) or hepatitis C (hepatitis C antibody);
• alcohol abuse (>20 g/day (2 standard drinks) in women or > 30 g/d (3 drinks) in men over a two-year period);
• drug-induced liver disease, Wilson's disease, hereditary deficiency of antitrypsin-1 and idiopathic hemochromatosis;
• history of decompensated liver disease including ascites, encephalopathy or variceal bleeding;
• regular use of an agents with gut microbiota modulation activity (antibiotic, pro-, pre-, post or synbiotics supplement etc.) within 3 months prior to enrollment;
• allergy on probiotics or their components;
• use of agents such as vitamin E, omega-3 fatty acids or medications with evidence for effects on NAFLD (pioglitazone, GLP-1 analogues, dipeptidyl peptidase IV inhibitors, ursodeoxycholic acid);
• subjects with a history of bariatric surgery or significant weight loss (> 5% body weight) or rapid weight loss (> 1.6kg/week), within 6 months prior to enrollment;
• uncontrolled cardiovascular or respiratory disease, decompensated liver disease including ascites, encephalopathy or variceal bleeding, active malignancy, or chronic infections;
• participant who had severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated), and/or had a confirmed case of COVID-19 within 4 weeks prior to enrollment;
• participation in other clinical trials;
• presence of pregnancy or lactation.

Related Conditions & MeSH terms

• Fatty Liver
• Hepatic Steatosis
• Liver Diseases

Intervention

Dietary Supplement:
• Probiotic lysate (postbiotic and metabiotc)
Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
• Placebo
Placebo

Locations

Country	Name	City	State
Ukraine	Bogomolets National Medical University	Kyiv
Ukraine	Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine	Kyiv
Ukraine	Kyiv City Clinical Endocrinology Center	Kyiv
Ukraine	Taras Shevchenko National University of Kyiv	Kyiv
Ukraine	Danylo Halytsky Lviv National Medical University	Lviv

Sponsors (7)

Lead Sponsor	Collaborator
Bogomolets National Medical University	Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine, Danylo Halytsky Lviv National Medical University, Kyiv City Clinical Endocrinology Center, MirImmunoFarm, Stellar Biotics, Taras Shevchenko National University of Kyiv

Country where clinical trial is conducted

Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	changes in fatty liver index (FLI)	FLI = [e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745)] × 100	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Primary	hepatic steatosis index (HSI)	HSI = 8 x ALT/AST + BMI(+ 2 if type 2 diabetes yes, + 2 if female)	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Primary	TyG index	TyG = ln [Fasting triglyceride (mg / dl) x Fasting glucose (mg / dl)] / 2	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of AST	AST in IU/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of ALT	ALT in IU/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of Gamma-glutamyl Transferase (GGT)	GGT in IU/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of Total Cholesterol (TC)	TC in mmol/l	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of Tryglicerides (TG)	TG in mmol/l	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of LDL-Cholesterol (LDL-C)	LDL-C in mmol/l	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of VLDL-Cholesterol (VLDL-C)	VLDL-C in mmol/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of HDL-Cholesterol (HDL-C)	HDL-C in mmol/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of high sensitivity CRP (hs-CRP)	hs-CRP in mg/L	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	Concentration of IL-6	IL-6 in pg/mL	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	waist circumferences (WC)	WC in cm	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	body mass index (BMI)	weight in kg and height in meters will be combined to report BMI in kg/m^2	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]
Secondary	visceral fat content	visceral fat content using electronic scales-analyzers of body composition Tanita Scale BC-601	at 3 month (end of treatment) and 6 month (follow-up period) compared to baseline]